| Quantity: | |
|---|---|
Creatine Kinase Isoenzyme (CK-MB) is a gold standard biomarker for the early diagnosis of acute myocardial infarction (AMI). Our CK-MB Test Kit is a high-specificity in vitro diagnostic reagent developed for the quantitative detection of CK-MB activity in human serum samples. The product is specially designed for emergency departments, cardiac care units, and clinical laboratories, which can quickly and accurately detect the increase of CK-MB levels in patients, assist in the early diagnosis of AMI, estimate the size of myocardial infarction, and judge the possibility of re-infarction. With its fast detection speed, high specificity, and good repeatability, our CK-MB Test Kit has become an essential tool for the rapid diagnosis and monitoring of myocardial infarction, providing strong support for saving the lives of patients with acute myocardial infarction.
Parameter | Details |
Detection Method | Enzyme-Linked Immunosorbent Assay (ELISA) |
Sample Type | Human Serum (non - hemolyzed sample preferred) |
Detection Range | 0.5 - 50 ng/mL |
Sensitivity | ≤ 0.2 ng/mL |
Intra - Assay CV | ≤ 4.0% |
Inter - Assay CV | ≤ 6.0% |
Storage Condition | 2 - 8℃, sealed and stored away from light |
Shelf Life | 12 months from the date of manufacture |
Applicable Instruments | Compatible with semi-automatic and fully automatic ELISA analyzers |
The kit can complete the entire detection process within 30 minutes, which is especially suitable for the emergency diagnosis of AMI. It can provide test results in the shortest time, helping clinicians make treatment decisions quickly and win the golden time for patients.
The kit uses monoclonal antibodies targeting CK-MB, which can specifically identify CK-MB isoenzymes, and effectively avoid interference from other isoenzymes such as CK-MM and CK-BB, ensuring the accuracy of test results and reducing the rate of misdiagnosis.
The reagent has good batch-to-batch consistency and repeatability, which can accurately detect the dynamic changes of CK-MB levels in patients, help estimate the size of myocardial infarction, and judge whether re-infarction occurs after treatment.
In the early stage of AMI (within 3 - 8 hours after the onset of symptoms), the CK-MB level in patients will rise significantly. The kit can quickly detect this change and realize the early diagnosis of AMI.
The peak value of CK-MB activity is positively correlated with the size of myocardial infarction. The kit can quantify CK-MB levels, helping clinicians estimate the scope of myocardial damage and formulate targeted treatment plans.
After AMI patients receive treatment, if the CK-MB level that has decreased rises again, it indicates the possibility of re-infarction. The kit can realize continuous dynamic monitoring and timely warn of re-infarction risks.
It is used to monitor the CK-MB level of patients after cardiac surgery, evaluate the recovery of myocardial function, and detect potential myocardial injury in time.
The product is developed for the urgent needs of AMI diagnosis, with a fast detection speed and simple operation steps, which can be quickly put into use in emergency scenarios and improve the emergency response capacity of medical institutions.
The kit has passed a large number of clinical trials, and the test results are highly consistent with the results of the gold standard detection method. It has been recognized by many authoritative hospitals and has a good clinical application foundation.
On the premise of ensuring high quality, we adopt an optimized production process to reduce the production cost of the product, providing customers with cost-effective detection solutions without reducing the performance of the product.
For manual operation, the test results can be obtained within 30 minutes; when used with a fully automatic ELISA analyzer, the detection time can be shortened to 20 minutes, which is suitable for emergency testing needs.
Yes, hemolysis will release a large amount of CK from red blood cells, which will interfere with the test results. It is recommended to use non-hemolyzed serum samples for testing.
The kit is mainly used for the diagnosis and monitoring of AMI. For other cardiac diseases such as myocarditis, it can be used as an auxiliary diagnostic index combined with other clinical indicators.
Do you need a fast and accurate CK-MB detection tool to improve the emergency diagnosis level of acute myocardial infarction? Don't hesitate to contact us! Inquire about the latest product quotations, request professional technical guidance, and apply for free trial samples. Let our CK-MB Test Kit help you save more patients with acute myocardial infarction, and we look forward to cooperating with you!
